Suchergebnisse - "Kazandjian, Dickran"

PubPharm (5)

1

A Benefit-Risk Analysis Approach to Capture Regulatory Decision-Making : Multiple Myeloma

enthalten in: Clinical pharmacology and therapeutics | 2018

von Raju, G. | Gurumurthi, K. | Domike, R. | +6

2

Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials : A Meta-analysis

enthalten in: JAMA oncology | 2017

von Blumenthal, G. | Zhang, L. | Zhang, H. | +7

3

FDA Approval Summary : Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy

enthalten in: The oncologist | 2016

von Kazandjian, D. | Suzman, D. | Blumenthal, G. | +5

CommentIn: Oncologist. 2016 Dec;21(12 ):e3. - PMID 27864576

4

FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2016

von Kazandjian, D. | Blumenthal, G. | Yuan, W. | +3

5

FDA approval summary : crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements

enthalten in: The oncologist | 2014

von Kazandjian, D. | Blumenthal, G. | Chen, H. | +5

1
[1]